Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Researchers developing new arsenal in war against cancer

16.12.2002


In the battle against cancer, Virginia Tech researchers have developed a potential warhead to better kill cancer cells, a new missile to deliver the warhead more efficiently to the diseased areas, and a new detonation device once the warhead is in place.



In a cross-disciplinary effort, the researchers, using photodynamic therapy (PDT), have obtained results in three different areas that, used together, have the possibility of providing more efficient, less invasive, and more specific treatments for cancer and other diseases such as age-related macular-degeneration.

A long-term concept has held that one should be able to use light-activated compounds to kill diseased cells, said Karen Brewer, associate professor of chemistry. The researchers have developed new tri-metallic supra-molecules that can be positioned in exact parts of cancer cells and excited by a therapeutic wavelength at which light propagates efficiently through tissue. Only when the light hits the supra-molecules do they become toxic to the cancer cells.


The advantages are many. The non-surgical process avoids the debilitating side effects of normal chemotherapy. The system enables the scientists to place the supra-molecules at specific locations in cells and to deliver light activating the cancer-killing molecules directly at that spot in a strength that does not harm other tissue. "This allows much lower dosages of light to be effective, so we can use agents that are more aggressive and not get the side effects of chemotherapy," Brewer said.

Researchers Shawn Swavey and Alvin Holder, along with students Lee Williams and Nathan Toft, working in the Brewer laboratory, developed the new mixed-metal supra-molecular complexes (medicines) that Brewer and Brenda Winkel, professor of biology, have proven are capable of photo-cleaving DNA, a normal therapeutic target in cells. The complexes are novel molecules whose chemistry allows the researchers to append them to other units.

At present, physicians use a chemical that is exposed to light and activates oxygen in photodynamic therapy. In tumor cells, oxygen is depleted rapidly, so those treatments can run out of oxygen and not kill the entire tumor, which can return. Brewer’s new systems don’t need oxygen, and the researchers can change the wavelength of light used. "We can fine tune the compound for light-absorbing characteristics," Brewer said. "By using a lower energy, we can better penetrate the body."

Brian Storrie, professor of biochemistry, and research scientist Maria Teresa Tarrago-Trani of biochemistry have developed the "rocket" with which to deliver the cancer-killing agents to particular organelles, or parts, in the cancer cells. "We have used a polypeptide that binds to a cell surface receptor, and that molecule is over-expressed for certain cancers. We can deliver photosynthesizers to the cancer," Storrie said.

The delivery vehicle is a B-fragment of a class of toxins known as shiga toxins. The A fragment is toxic, but the B fragment is a non-toxic delivery system. Storrie developed a way to use the B fragment to deliver the photo-dynamic agents developed by Brewer into the cells. This enables the researchers to target certain kinds of cancer cells that have receptors for the B fragment and deliver the agent to the exact spot in the cell so the supra-molecule can attack that part. This allows for the destruction of many parts in the cancerous cells.

Ken Meissner, senior research scientist with the Optical Science and Engineering Research (OSER) Center at Virginia Tech is developing the "detonation device" for the supra-molecules, which are nontoxic until hit by light. His specialty is the delivery of light to the correct tissues and to the supra-molecules positioned to kill the cells. Meissner develops better ways to get the light to the tumor and to understand how light passes through tissue

Together, the three-part attack opens up huge new areas for fighting cancer. "We can attach the delivery vehicles, change the light we need, change the biological target in the cells, and design a molecule that reacts with that part," Brewer said. In other words, Brewer can develop different molecules for different areas of the cells, Storrie can develop ways to get those molecules to the right places in the cells, and Meissner can develop methods to deliver the light needed to begin the killing of cancer cells. Or, Meissner can develop a new light-delivery system to work in a certain area, and then Brewer can develop a molecule that will kill tumor cells when excited with this light, and Storrie can get the molecule there.

The possibilities are greatly expanded by the variety of supra-molecules and the interactive work of these researchers. This exciting work is in the early stages, but the researchers hope it will someday be the basis for important strides in the treatment of cancer and other diseases.

The research is being done within the OSER Photodynamics Mini-center, a joint effort between the Carilion Biomedical Institute and Virginia Tech. Research groups collaborating under the mini-center include researchers Brewer, Storrie, Meissner, and Winkel, and Yannis Besieris and Brad Davis of electrical and computer engineering, Sun Young Kim of biochemistry, and Ed Wojcik of biology, all of Virginia Tech


Researcher contact information:
Karen Brewer 540-231-6579, kbrewer@vt.edu,
Brian Storrie 540-231-6434, storrie@vt.edu,
Ken Meissner 540-231-2512, cmeissne@vt.edu

PR CONTACT: Sally Harris 540-231-6759 slharris@vt.edu


Karen Brewer | EurekAlert!
Further information:
http://www.chem.vt.edu/chem-dept/brewer/brewer.html
http://www.biochem.vt.edu/faculty/storrie.html

More articles from Health and Medicine:

nachricht Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign

nachricht Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

An innovative high-performance material: biofibers made from green lacewing silk

20.01.2017 | Materials Sciences

Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery

20.01.2017 | Life Sciences

Bodyguards in the gut have a chemical weapon

20.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>